Toll Free: 1-888-670-5445
Suite 101, 2011-94 St. Edmonton, AB T6N 1H1 Canada
bioFILM PA TM first test to help in fight against serious lung infections
A new test lets doctors more accurately identify the right antibiotics to treat serious, chronic infections that are biofilm based. For people with cystic fibrosis, that’s good news.
More than 80 per cent of infections are caused by biofilms. This new breakthrough test,
bioFILM PATM, is of immense significance to the medical community.
New treatment against bacteria and fungus in select crops has potential to increase world’s food production.
 |
AgressTM is a novel seed treatment developed by Innovotech that is currently going through registration in the USA and Canada.
Cystic Fibrosis blog
Our new Cystic Fibrosis blog reaches out to the cystic fibrosis community on what Innovotech's recent health announcement means to patients.
- Test now available for CF patients
- Clinical research started in 2007 at the Adult Cystic Fibrosis Clinic, University of Alberta Hospital, Edmonton shows bioFILM PA TM effective in treating serious, life-threatening lung infections
- Important information on bioFILM PA TM for physicians and other health providers
Investor News
|
Our Services
Innovotech solves client biofilm problems through its Contract Research department. We have a track record of both standardized and customized research to meet client needs.
The scope of research is from early stage identification of problems and screening of agents for "anti-biofilm activity”, to research acceptable to regulatory agencies for product claim validation, to post-market product comparisons for marketing purposes.
Innovotech regularly develops in vitro models of the client specific situation as a starting point that enables any number of test parameters to be tested